Trial
NCT02477748
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
Phase IIITERMINATEDSAFETYConfidence: HIGH
Sponsor
Alcobra Ltd.
Collaborators
—
Condition
Attention Deficit Hyperactivity Disorder (ADHD)
Intervention
MDX
Why stopped
FDA Clinical hold
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-01-19